 | • レポートコード：TPM-B04274 • 出版社/出版日：Transparency Market Research / 2017年11月 • レポート形態：英文、PDF、170ページ • 納品方法：Eメール • 産業分類：製薬・医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、抗肥満処方薬の世界市場について調べ、抗肥満処方薬の世界規模、市場動向、市場環境、薬剤分類別分析、年齢層別分析、流通経路別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・抗肥満処方薬の世界市場動向 ・抗肥満処方薬の世界市場環境 ・抗肥満処方薬の世界市場規模 ・抗肥満処方薬の世界市場規模：薬剤分類別 ・抗肥満処方薬の世界市場規模：年齢層別 ・抗肥満処方薬の世界市場規模：流通経路別 ・抗肥満処方薬の世界市場：地域別市場規模・分析 ・抗肥満処方薬の北米市場規模・予測 ・抗肥満処方薬のアメリカ市場規模・予測 ・抗肥満処方薬の中南米市場規模・予測 ・抗肥満処方薬のヨーロッパ市場規模・予測 ・抗肥満処方薬のアジア市場規模・予測 ・抗肥満処方薬の日本市場規模・予測 ・競争状況・関連企業情報 |
Global Anti-Obesity Prescription Drugs Market: Overview
The global anti-obesity prescription drugs market is expected to witness a moderate growth attributed to growing prevalence of obesity globally. Moreover, surge in consumption of unhealthy food products that are rich in cholesterol has led to an upsurge in demand anti-obesity prescription drugs. Increasing level of chronic stress also contributes towards obesity. Moreover, consumption of psychotropic and diabetic drugs is expected to impact growth of the global anti-obesity prescription drugs market during the forecast period.
The report provides an in-depth insight on some important aspects of the global anti-obesity prescription drugs market and offers insights on the growth patterns, various factors fuelling growth of the global market, competitive landscape and important segments.
Global Anti-Obesity Prescription Drugs Market: Dynamics
Growth of the global anti-obesity prescription drugs market will mainly remain bound to various macro-economic and micro-economic factors. The report further reveals that the global anti-obesity prescription drugs market is increasingly driven by growing prevalence of obesity globally. Consumption of the food products that are rich in cholesterol continues to contribute towards obesity. Growing consumption of alcoholic beverages will also lead to increase in obesity during the forecast period.
Growing prevalence of depression has led to increasing consumption of the psychotropic drugs. Increasing side-effects of the psychotropic drug has contributed towards obesity. Growing prevalence of obesity due to increasing side-effects of psychotropic drugs has led to an upsurge in demand for obesity management. Moreover, increasing prevalence of diabetes has revved up consumption of medications such as sulfonylureas, insulin and thizolidinediones. These medications have appetite stimulating features, due to which the patients tend to eat more. Eating disorders due to antidepressants and diabetic drugs has continued to contribute towards obesity. Increasing demand for obesity management is expected to impact growth of the global anti-obesity prescription drugs market positively.
Obesity has also witnessed to be a result of increasing chronic stress globally. Increasing emotional and physical stress level leads the brain to release cortisol hormones. Release of the cortisol hormones further stimulates a person’s appetite, due to which people tend to eat unhealthy food products. Increasing consumption of unhealthy food products helps people to counter their emotional and physical stress. Growing prevalence of obesity due to increasing level of stress has further led to an upsurge in demand for obesity management. Bound to these factors, the global anti-obesity prescription drugs market is expected to witness significant growth.
Global Anti-Obesity Prescription Drugs Market: Segmentation
The global anti-obesity prescription drugs market is mainly segmented into drug class, age group, distribution channel, and region. On the basis drug class, the global market is expected to be segmented as Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate and Liraglutide. Based on age group, the global market is segmented as Pediatric and Adult. By distribution channel, the global market is segmented as Hospitals Pharmacies, Retail Pharmacies and E-commerce.
Global Anti-Obesity Prescription Drugs Market: Competition
Key players in the global anti-obesity prescription drugs market are VIVUS, Inc, Orexigen Therapeutics, Inc, Novo Nordisk A/S, F Hoffmann La Roche Ltd and Arena Pharmaceuticals, Inc.
レポート目次1. Global Anti-Obesity Prescription Drugs Market – Executive Summary
2. Global Anti-Obesity Prescription Drugs Market Overview
2.1. Introduction
2.1.1. Global Anti-Obesity Prescription Drugs Market Taxonomy
2.1.2. Global Anti-Obesity Prescription Drugs Market Definition
2.2. Global Anti-Obesity Prescription Drugs Market Size (US$ Mn) and Forecast, 2012-2026
2.2.1. Global Anti-Obesity Prescription Drugs Market Y-o-Y Growth
2.3. Global Anti-Obesity Prescription Drugs Market Dynamics
2.4. Supply Chain
2.5. Cost Structure
2.6. Pricing Analysis
2.7. PESTLE Analysis
2.8. Product Life Cycle Analysis
2.9. Key Regulations
2.10. Patents
2.11. List of Distributors
2.12. Key Participants Market Presence (Intensity Map) By Region
3. Global Anti-Obesity Prescription Drugs Market Analysis and Forecast 2012-2026
3.1. Global Anti-Obesity Prescription Drugs Market Size and Forecast By Drug Class, 2012-2026
3.1.1. Bupropion and Naltrexone Market Size and Forecast, 2012-2026
3.1.1.1. Revenue (US$ Mn) Comparison, By Region
3.1.1.2. Market Share Comparison, By Region
3.1.1.3. Y-o-Y growth Comparison, By Region
3.1.2. Orlistat Market Size and Forecast, 2012-2026
3.1.2.1. Revenue (US$ Mn) Comparison, By Region
3.1.2.2. Market Share Comparison, By Region
3.1.2.3. Y-o-Y growth Comparison, By Region
3.1.3. Lorcaserin Market Size and Forecast, 2012-2026
3.1.3.1. Revenue (US$ Mn) Comparison, By Region
3.1.3.2. Market Share Comparison, By Region
3.1.3.3. Y-o-Y growth Comparison, By Region
3.1.4. Phentermine and Topiramate Market Size and Forecast, 2012-2026
3.1.4.1. Revenue (US$ Mn) Comparison, By Region
3.1.4.2. Market Share Comparison, By Region
3.1.4.3. Y-o-Y growth Comparison, By Region
3.1.5. Liraglutide Market Size and Forecast, 2012-2026
3.1.5.1. Revenue (US$ Mn) Comparison, By Region
3.1.5.2. Market Share Comparison, By Region
3.1.5.3. Y-o-Y growth Comparison, By Region
3.2. Global Anti-Obesity Prescription Drugs Market Size and Forecast By Age Group, 2012-2026
3.2.1. Pediatric Market Size and Forecast, 2012-2026
3.2.1.1. Revenue (US$ Mn) Comparison, By Region
3.2.1.2. Market Share Comparison, By Region
3.2.1.3. Y-o-Y growth Comparison, By Region
3.2.2. Adult Market Size and Forecast, 2012-2026
3.2.2.1. Revenue (US$ Mn) Comparison, By Region
3.2.2.2. Market Share Comparison, By Region
3.2.2.3. Y-o-Y growth Comparison, By Region
3.3. Global Anti-Obesity Prescription Drugs Market Size and Forecast By Distribution Channel, 2012-2026
3.3.1. Hospitals Pharmacies Market Size and Forecast, 2012-2026
3.3.1.1. Revenue (US$ Mn) Comparison, By Region
3.3.1.2. Market Share Comparison, By Region
3.3.1.3. Y-o-Y growth Comparison, By Region
3.3.2. Retail Pharmacies Market Size and Forecast, 2012-2026
3.3.2.1. Revenue (US$ Mn) Comparison, By Region
3.3.2.2. Market Share Comparison, By Region
3.3.2.3. Y-o-Y growth Comparison, By Region
3.3.3. E-commerce Market Size and Forecast, 2012-2026
3.3.3.1. Revenue (US$ Mn) Comparison, By Region
3.3.3.2. Market Share Comparison, By Region
3.3.3.3. Y-o-Y growth Comparison, By Region
4. North America Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026
4.1. Revenue (US$ Mn) Comparison, By Country
4.2. Revenue (US$ Mn) Comparison, By Drug Class
4.3. Revenue (US$ Mn) Comparison, By Age Group
4.4. Revenue (US$ Mn) Comparison, By Distribution Channel
5. Latin America Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026
5.1. Revenue (US$ Mn) Comparison, By Country
5.2. Revenue (US$ Mn) Comparison, By Drug Class
5.3. Revenue (US$ Mn) Comparison, By Age Group
5.4. Revenue (US$ Mn) Comparison, By Distribution Channel
6. Europe Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026
6.1. Revenue (US$ Mn) Comparison, By Country
6.2. Revenue (US$ Mn) Comparison, By Drug Class
6.3. Revenue (US$ Mn) Comparison, By Age Group
6.4. Revenue (US$ Mn) Comparison, By Distribution Channel
7. Japan Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026
7.1. Revenue (US$ Mn) Comparison, By Country
7.2. Revenue (US$ Mn) Comparison, By Drug Class
7.3. Revenue (US$ Mn) Comparison, By Age Group
7.4. Revenue (US$ Mn) Comparison, By Distribution Channel
8. APEJ Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026
8.1. Revenue (US$ Mn) Comparison, By Country
8.2. Revenue (US$ Mn) Comparison, By Drug Class
8.3. Revenue (US$ Mn) Comparison, By Age Group
8.4. Revenue (US$ Mn) Comparison, By Distribution Channel
9. MEA Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026
9.1. Revenue (US$ Mn) Comparison, By Country
9.2. Revenue (US$ Mn) Comparison, By Drug Class
9.3. Revenue (US$ Mn) Comparison, By Age Group
9.4. Revenue (US$ Mn) Comparison, By Distribution Channel
10. Global Anti-Obesity Prescription Drugs Market Company Share, Competition Landscape and Company Profiles
10.1. Company Share Analysis
10.2. Competition Landscape
10.3. Company Profiles
10.3.1. VIVUS Inc.
10.3.2. Novo Nordisk A/S
10.3.3. GlaxoSmithKline PLC
10.3.4. Roche Holding AG
10.3.5. Arena Pharmaceuticals, Inc.
10.3.6. Orexigen Therapeutics, Inc.
10.3.7. Merck & Co Inc.
10.3.8. Sun Pharmaceutical Industries Limited
10.3.9 Takeda Pharmaceutical Company Limited
10.3.10 Pfizer Inc.
11. Research Methodology
12. Secondary and Primary Sources
13. Assumptions and Acronyms
14. Disclaimer
List of TablesTABLE 1 Global Anti-Obesity Prescription Drugs Market Value (US$ Mn), 2012-2017
TABLE 2 Global Anti-Obesity Prescription Drugs Market Value (US$ Mn), 2018-2026
TABLE 3 Global Anti-Obesity Prescription Drugs Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global Bupropion and Naltrexone Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global Bupropion and Naltrexone Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global Bupropion and Naltrexone Segment Market Share, By Region 2012-2017
TABLE 7 Global Bupropion and Naltrexone Segment Market Share, By Region 2018-2026
TABLE 8 Global Bupropion and Naltrexone Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global Orlistat Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global Orlistat Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global Orlistat Segment Market Share, By Region 2012-2017
TABLE 12 Global Orlistat Segment Market Share, By Region 2018-2026
TABLE 13 Global Orlistat Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global Lorcaserin Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global Lorcaserin Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global Lorcaserin Segment Market Share, By Region 2012-2017
TABLE 17 Global Lorcaserin Segment Market Share, By Region 2018-2026
TABLE 18 Global Lorcaserin Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Phentermine and Topiramate Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Phentermine and Topiramate Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Phentermine and Topiramate Segment Market Share, By Region 2012-2017
TABLE 22 Global Phentermine and Topiramate Segment Market Share, By Region 2018-2026
TABLE 23 Global Phentermine and Topiramate Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Liraglutide Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Liraglutide Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Liraglutide Segment Market Share, By Region 2012-2017
TABLE 27 Global Liraglutide Segment Market Share, By Region 2018-2026
TABLE 28 Global Liraglutide Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Pediatric Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Pediatric Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Pediatric Segment Market Share, By Region 2012-2017
TABLE 32 Global Pediatric Segment Market Share, By Region 2018-2026
TABLE 33 Global Pediatric Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Adult Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Adult Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Adult Segment Market Share, By Region 2012-2017
TABLE 37 Global Adult Segment Market Share, By Region 2018-2026
TABLE 38 Global Adult Segment Y-o-Y, By Region 2017-2026
TABLE 39 Global Hospitals Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 40 Global Hospitals Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 41 Global Hospitals Pharmacies Segment Market Share, By Region 2012-2017
TABLE 42 Global Hospitals Pharmacies Segment Market Share, By Region 2018-2026
TABLE 43 Global Hospitals Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 44 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 45 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 46 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
TABLE 47 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
TABLE 48 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 49 Global E-commerce Segment Value (US$ Mn), By Region 2012-2017
TABLE 50 Global E-commerce Segment Value (US$ Mn), By Region 2018-2026
TABLE 51 Global E-commerce Segment Market Share, By Region 2012-2017
TABLE 52 Global E-commerce Segment Market Share, By Region 2018-2026
TABLE 53 Global E-commerce Segment Y-o-Y, By Region 2017-2026
TABLE 54 North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
TABLE 55 North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
TABLE 56 North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 57 North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 58 North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
TABLE 59 North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
TABLE 60 North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 61 North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 62 Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
TABLE 63 Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
TABLE 64 Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 65 Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 66 Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
TABLE 67 Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
TABLE 68 Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 69 Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 70 Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
TABLE 71 Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
TABLE 72 Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 73 Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 74 Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
TABLE 75 Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
TABLE 76 Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 77 Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 78 Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
TABLE 79 Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
TABLE 80 Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 81 Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 82 Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
TABLE 83 Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
TABLE 84 Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 85 Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 86 APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
TABLE 87 APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
TABLE 88 APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 89 APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 90 APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
TABLE 91 APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
TABLE 92 APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 93 APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 94 MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
TABLE 95 MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
TABLE 96 MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 97 MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 98 MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
TABLE 99 MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
TABLE 100 MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 101 MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026